Loading...
XJPX4572
Market cap34mUSD
Jan 09, Last price  
287.00JPY
1D
-0.35%
1Q
-14.58%
Jan 2017
-86.49%
IPO
-69.37%
Name

Carna Biosciences Inc

Chart & Performance

D1W1MN
XJPX:4572 chart
P/E
—
P/S
3.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.65%
Rev. gr., 5y
16.59%
Revenues
1.63b
+17.24%
499,570,000687,013,000571,800,000592,549,000510,829,000771,464,000611,760,0001,569,205,000811,598,000657,516,000754,691,0003,207,423,0001,133,346,0002,017,529,0001,386,748,0001,625,889,000
Net income
-1.15b
L-14.57%
-503,039,000-315,397,000-397,107,000-361,651,000-449,994,000-282,343,000-846,717,000456,388,000-289,940,000-737,264,000-1,210,573,000828,289,000-1,111,032,000-534,474,000-1,349,539,000-1,152,895,000
CFO
-1.68b
L+136.80%
-267,673,000-419,603,000-309,950,000-350,453,000-425,183,000-247,034,000-468,976,000401,645,000-452,967,000-561,055,000-1,128,026,0001,477,773,000-1,260,972,000-1,536,612,000-708,390,000-1,677,464,000

Profile

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.
URL
https://www.carnabio.com/
IPO date
Mar 25, 2008
Employees
64
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,625,889
17.24%
1,386,748
-31.27%
Cost of revenue
2,079,152
2,053,869
Unusual Expense (Income)
NOPBT
(453,263)
(667,121)
NOPBT Margin
Operating Taxes
22,048
26,140
Tax Rate
NOPAT
(475,311)
(693,261)
Net income
(1,152,895)
-14.57%
(1,349,539)
152.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,343,338
600,824
BB yield
-15.32%
-8.48%
Debt
Debt current
126,569
151,988
Long-term debt
90,971
148,402
Deferred revenue
Other long-term liabilities
40,032
39,799
Net debt
(2,722,561)
(3,137,658)
Cash flow
Cash from operating activities
(1,677,464)
(708,390)
CAPEX
(11,530)
(126,001)
Cash from investing activities
(11,376)
(125,696)
Cash from financing activities
1,182,027
367,006
FCF
(1,121,033)
(217,272)
Balance
Cash
2,889,101
3,379,048
Long term investments
51,000
59,000
Excess cash
2,858,807
3,368,711
Stockholders' equity
(1,949,925)
(1,491,389)
Invested Capital
6,050,464
5,442,759
ROIC
ROCE
EV
Common stock shares outstanding
16,800
13,617
Price
522.00
0.38%
520.00
-52.81%
Market cap
8,769,644
23.85%
7,081,017
-49.39%
EV
6,048,070
3,943,359
EBITDA
(417,651)
(633,313)
EV/EBITDA
Interest
3,451
5,310
Interest/NOPBT